Australian Hepatitis and Risk Survey in Prisons (AusHep)

Kirby Institute

Status: Enrolling

Conditions: Hepatitis C; Hepatitis B; HIV Infections

Treatments: Diagnostic Test: Point-of-care hepatitis B surface antibody test; Diagnostic Test: Point-of-care hepatitis C RNA test; Diagnostic Test: Point-of-care HIV antibody test; Behavioral: Interview-style survey; Diagnostic Test: Point-of-care hepatitis B surface antigen test; Diagnostic Test: Point-of-care hepatitis C antibody test

Study type: Observational

Funder types: Other

Identifiers

NCT05839522

VISP1901

Details and patient eligibility

About

The Australian Hepatitis and risk survey in prisons (AusHep) is a national prison-based blood-borne virus (BBV) surveillance study. This biobehavioural survey involves point-of-care testing for hepatitis C (HCV) antibodies and RNA (if antibody positive), hepatitis B surface antigens, hepatitis B surface antibodies, and HIV surface antibodies, and an interview-style survey on prior testing and treatment history and engagement in risk behaviours. The study will recruit approximately 2400 prisoner participants from 25 representative prisons across Australia, annually.

Enrollment: 2,400 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Any remandee or sentenced prisoner who has provided informed consent is eligible to participate in the study.

Exclusion criteria

• Individuals who are unable or unwilling to provide consent or abide by the requirements of the study, as assessed by the trained nurses. Some individuals may be considered unable to provide consent or abide by the requirements of the study if they are:

  • Too mentally unwell to provide consent
  • Profoundly intellectually impaired
  • Unable to speak English and comprehend the survey.

Those excluded from participating in the study will be referred to the local prison clinic service for standard of care.

Trial design

2,400 participants in 1 patient group

Persons in custody in Australia

Description:

Representative sample of 2400 people in prison from 25 representative prisons in Australia will participate in a biobehavioural survey involving point-of-care testing for HCV antibodies and RNA (if antibody positive), HBV surface antigens and antibodies, and HIV antibodies, and an interview-style survey.

Treatment:

Diagnostic Test: Point-of-care hepatitis B surface antigen test

Diagnostic Test: Point-of-care hepatitis C antibody test

Diagnostic Test: Point-of-care HIV antibody test

Diagnostic Test: Point-of-care hepatitis C RNA test

Behavioral: Interview-style survey

Diagnostic Test: Point-of-care hepatitis B surface antibody test